Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Phase III Trial of SHR-1210 in Combination With Famitinib or Placebo Plus Chemotherapy in Subjects With Non-squamous Non-small-cell Lung Cancer.

NCT04619433 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT04619433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04619433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Phase III Trial of SHR-1210 in Combination With Famitinib or Placebo Plus Chemotherapy in Subjects With Non-squamous Non-small-cell Lung Cancer.
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
February 1, 2021
Completion date
August 16, 2025
Enrollment
48 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small-cell lung cancer